PDCD1 and neoplasm: In contrast, clinically, inhibitors targeting the CTLA-4 pathway and PD-1/PD-L1 inhibitors exert their clinical effects by antagonizing the respective receptor and unleashing T cells from their inhibitory states, which restores anti-tumor immunity.